Meet NeuroRx. Recognized as startup of the year by the Israeli Biotechnology Association and Israel’s Office of the Chief Scientist.

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Who should attend: Single Family Office investors and HNW investors, and strategic investors.

What: Opportunity to participate in preferred stock financing. More than $11 million has already been funded in this round, including lead head fund investor, C-Health led by the former President of Teva, and other family offices and HNW individuals. NeuroRx was recognized as startup of the year by the Israeli Biotechnology Association and Israel’s Office of the Chief Scientist.

Family Office Insights luncheon. 5.18.2017. Carii presenting.

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Carii. The first end-to-end digital platform for creating branded connected communities and deepening engagement and relationships – on both web and mobile apps."

Who: Single Family Office investors, HNW investors, Institutional and Strategic investors.

Family Office Insights luncheon – ECHO Payment Systems

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

What: This is an opportunity to participate in a Series-A-Round financing for a Fintech payment company with conservatively projected net revenue of over $100MM in five years. The company is actively sought out by financial institutions, global foreign exchange companies, check cashers, tax preparation services, and Fintech innovators all looking for ECHO to help them create the next “PayPal” or “Venmo” market breakthrough.

ECHO is an established Financial Technology (Fintech) company with a world class executive team that is uniquely qualified to help organizations develop customized physical, virtual and mobile payment applications.

Who should attend: Single Family Office investors, HNW investors, Institutional and Strategic investors.

Family Office Insights luncheon with Brabble

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Brabble, an Internet technology company that combines a social media platform with e-commerce via intellectual property.

Who Should Attend: Single Family Office investors, HNW investors, Institutional and Strategic investors.

What: Opportunity to participate in a round of Capital Financing of common stock. Almost $8 million has been raised to date privately. The current investment opportunity is for a new round of capital where we have begun to raise privately, as well as our first institutional investment group which has issued an LOI of $500k to join in this round in addition to them referring their network of family offices and HNW individuals to us. We are seeking an additional $4 million that will directly impact our growth and revenue over the next twelve months.

Reminder: Family Office Insights Luncheon

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Who should attend: Single Family Office investors, HNW investors, Institutional and Strategic investors.

What: Opportunity to participate in preferred stock financing. CogWellin is 6 months away from its launching its phase 1 trial for its Alzheimer’s disease drug. The founder has over 30 years of experience treating Alzheimer’s and has run all the clinical trials for Alzheimer’s drugs in the past 20 years, which allows CogWellin to complete the phase 1 proof-of-concept at a large discount. CogWellin is a privately held clinical stage pharmaceutical company developing an effective drug and diagnostic to treat Alzheimer’s disease and other inflammatory-related ailments. Alzheimer’s disease is a significant, difficult-to-diagnose medical need, and a breakthrough disease-modifying Alzheimer’s drug could have a market over $20 billion. Alzheimer’s disease is the sixth leading cause of death in the United States, costing the nation $236 billion in 2016. Arthritis affects more than 50 million people in the nation, and is characterized by inflammation. A product pipeline targeting both Alzheimer’s and inflammation could capture a multibillion dollar market.

Reminder: Lung Therapeutics leverages $27M in non-dilutive NIH grant funding to develop game-changing solutions for lung-related fibrosis

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Who should attend: Single Family Office investors, HNW investors, Institutional and Strategic investors

What: Opportunity to participate in Series B round of funding of up to $9M. $3.2M has already been funded in this round primarily by Series A investors, including lead investor Bios Partners and an SPV made up mostly of family offices and HNW individuals. Lung Therapeutics leverages more than $27M in non-dilutive NIH grant funding and has significant interest from big pharma for its fibrosis related assets. Fibrosis is one of the hottest areas in pharma right now, with increasing M&A activity related to promising drugs, even at an early stage.

Reminder First Look Opportunity: “Access Tomorrow’s Equity Today.”

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Who should attend: Single Family Office investors, HNW investors, Institutional and Strategic investors

What: Opportunity to invest in the Vistia-managed real estate vehicle (capped at $60mm) as well as participate in $1.5mm investment round in the Vistia Group LLC operating company.

Investor Luncheon with J. Todd Morley, founder and Chairman of G2 Investment Group

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

What: Opportunity to invest in G2 Investment Group Holding Company’s Series A. Use of proceeds is to capitalize new and existing growth opportunities. In addition, we will offer a $15mm friends and family round in our SaaS driven investment platform.

Who Should Attend: Single Family Office investors, HNW investors, Institutional and Strategic investors.

Investor Luncheon with  income real estate veteran, Amit Goenka of Nisus Finance

Mike Welsome

Wednesday December 31st, 1969 7:00 PM

 

Who Should Attend: Single Family Office investors, HNW investors, fixed income, real estate and strategic investors.

What: First time unique opportunity for US investors to invest in India Yield Max Fund, a portfolio of senior secured short and medium term hard cash loan bonds and covered bonds issued by reputed real estate development firms in India. Bonds are securitized by over 2x in free cash flows and 2x in liquid-able assets of late state residential projects in key micro markets in India. Limited participation window for global investors to co-invest into a diversified bond portfolio with an average tenure of 2 years, fixed IRRs of nearly 18% p.a.in INR (fully hedged USD IRR of ~14%) with high collateral value.